熱門資訊> 正文
AC Immune更新了帕金森病候选人中期试验的数据
2025-04-02 18:52
- AC Immune (NASDAQ:ACIU) added ~22% in the premarket on Wednesday after the Swiss biotech shared additional interim results from a mid-stage trial for ACI-7104.056, its experimental therapy targeted at the neurodegenerative disorder Parkinson’s disease.
- Citing immunogenicity data from its Phase 2 VacSYn clinical trial, AC Immune (NASDAQ:ACIU) said ACI-7104.056 led to a high level of antibodies against alpha-synuclein, which is believed to play a major role in causing PD.
- According to the company, after six months of treatment in the study for patients with early PD, the level of anti-a-syn antibodies seen following four immunizations of ACI-7104.056 was over 20-fold higher than that for placebo.
- The experimental therapy was well tolerated without any safety issues so far, AC Immune (NASDAQ:ACIU) added, noting its plans to share additional updates later this year.
More on AC Immune
- AC Immune: Leader In Dementia Therapies, A Space Littered With Failures
- Seeking Alpha’s Quant Rating on AC Immune
- Historical earnings data for AC Immune
- Financial information for AC Immune
推薦文章
華盛早報丨美國退休金突發！401K可投資加密貨幣；火箭製造商FLY上市首日暴漲34%
美國養老金投資或迎鉅變，特朗普頒令為401(k)納入加密貨幣等資產鋪路
外盤頭條：OpenAI發佈最強GPT-5；特朗普頒令允許養老金投資另類資產
美股機會日報丨重大利好！特朗普將允許養老金投資加密貨幣；多鄰國績后狂飆26%
一圖看懂 | 中芯國際Q2營收22.09億美元，同比增長16.2%，股東應占利潤同比減少19.5%
非農大修預示美國經濟拐點？又一聯儲官員拉響警報 降息呼聲漸高
新股申購 | 「減肥藥概念」 銀諾醫藥-B一手入場費3773.68港元，引入邁富時等基石投資者
驚現「烏龍指」？美債昨夜盤中閃崩引各方猜測 最詭異的是……
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
